Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin

Blood

Volumn 89, Issue 9, 1997, Pages 3243-3252

  Syed, Summer ^a,b   Schuyler, Philip D ^a,b   Kulczycky, Myron ^a,b   Sheffield, William P ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Canadian Red Cross Society   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTITHROMBIN; LEPIRUDIN;

ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; GENE FUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; THROMBOSIS PREVENTION;

EID: 0030942608     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3243     Document Type: Article

References (44)

1. Markwardt F: Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 15:269, 1991
2. Dunwiddie CT, Thornberry N, Bull H, Sardana M, Friedman P, Jacobs J, Simpson E: Antistasin, a leech-derived inhibitor of factor Xa: Kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 264:16694, 1989
3. Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide is a novel inhibitor of factor Xa. Science 248:593, 1990
4. Apitz-Castro R, Béguin S, Tablante A, Bartoli F, Holt JC, Hemker HC: Purification and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmondus rotundus). Thromb Haemost 73:94, 1994
5. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF: A GP Hb-IIIa-specific integrin antagonist from the venom of Sistrurus M. barbouri. J Biol Chem 266:9359, 1991
6. Dodt T, Machleidt W, Seemueller U, Machlev R, Fritz H: Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA. Biol Chem Hoppe Seyler 367:803, 1986
7. Stone RS, Hofsteenge J: Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25:4622, 1986
8. Rydel TJ, Ravichrandran KG, Tulinsky A, Bode W, Huber R, Fenton JW, Roitsch C: The structure of a complex of recombinant hirudin and human-a-thrombin. Science 249:277, 1990
9. Riehl-Bellon N, Carvallo D, Acker M, van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C: Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiaie. Biochemistry 28:2941, 1989
10. Talbot MD: Biology of recombinant hirudin (CGP 39393). A new prospect in the treatment of thrombosis. Semin Thromb Hemost 15:293, 1989
11. Markwardt F, Nowak G, Sturzebecher U, Walsmann P: Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta 46:237, 1987
12. Henschen A, Markwardt F, Walsmann P: Evidence for the identity of hirudin isolated after kidney passage with the starting material. Folia Haematol 115:59, 1988
13. Turpie AGG, Weitz JI, Hirsh J: Advances in antithrombotic therapy: Novel reagents. Thromb Haemost 74:565, 1995
14. Markwardt M, Richter P, Walsmann G, Riesener G, Paintz M: Preparation of dextran-bound recombinant hirudin and ils pharmacokinetic behaviour. Biomed Biochim Acta 49:1103, 1990
15. Zawilska K, Zozulinska M, Turowiecka Z, Blahut M, Drobnik L, Vinazzer H: The effect of a long-lasting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIG) in rabbits. Thromb Res 69:315, 1993
16. GUSTO lib Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775, 1996
17. Peters T Jr: Serum albumin. Adv Protein Chem 37:161, 1985
18. Moore DD: Gene synthesis: Assembly of target sequences using mutually priming long oligonucleotides, in Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds): Current Protocols in Molecular Biology. Media, PA, Wiley, 1987, p 3.5.8
19. D'Aquila RT, Bechtel LJ, Videler JA, Eron JJ, Gorczyca P, Kaplan JC: Maximizing sensitivity and specificity of PCR by preamplification heating. Nucleic Acids Res 19:3749, 1991
20. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
21. Sheffield WP, Brothers AB, Hatton MWC, Clarke BJ, Blajchman MA: Molecular cloning and expression of rabbit antithrombin III. Blood 79:2330, 1992
22. Sheffield WP, Schuyler PD, Blajchman MA: Molecular cloning and expression of rabbit heparin cofactor II: A plasma thrombin inhibitor highly conserved between species. Thromb Haemost 71:778, 1994
23. Wu GY, Wilson GM, Shabby F, Grossman M, Shafritz DA, Wu CH: Receptor-mediated gene delivery in vivo: Partial correction of genetic analbuminemia in rats. J Biol Chem 266:14338, 1991
24. Henikoff S: Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing. Gene 28:351, 1984
25. Green S, Isseman I, Sheer E: A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16:369, 1988
26. Poison A, von Wechmar MB, van Regenmortel MH: Isolation of viral IgY antibodies from yolks of immunized hens. Immunol Commun 9:475, 1980
27. Sheffield WP, Blajchman MA: Amino acid substitutions of the P2 residue of antithrombin that either enhance or impair function. Thromb Res 75:293, 1994
28. Carson ER, Jones EA: Use of kinetic analysis and mathematical modeling in the study of metabolic pathways in vivo. N Engl J Med 300:1016, 1979
29. Carlson TH, Atencio AC, Simon TB: In vivo behaviour of radioiodinated rabbit antithrombin III. Demonstration of a non-circulating vascular compartment. J Clin Invest 74:191, 1984
30. Carlson TH, Atencio AC, Simon TH: Comparison of the behaviour in vivo of two molecular forms of antithrombin III. Biochem J 225:557, 1985
31. Sheffield WP, Castillo JE, Blajchman MA: Intracellular events determine the fate of antithrombin Utah. Blood 86:3461, 1995
32. Komatsu Y, Noda A, Misawa S, Sukesada A, Hiyasa H: CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. Biochem Biophys Res Commun 196:773, 1993
33. Dugiaczyk A, Law SW, Dennison OE: Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc Natl Acad Sei USA 79:71, 1982
34. Ho JX, Holowachuk EW, Norton EJ, Twigg PD, Carter DC: X-ray and primary structure of horse serum albumin (Equus caballus) at 0.27 nm resolution. Eur J Biochem 215:205, 1993
35. Travis J, Pannell R: Selective removal of albumin from plasma by affinity chromatography. Clin Chim Acta 49:49, 1973
36. Hatton MWC, Ross-Ouellet B: Radiolabeled r-hirudin as a measure of thrombin activity at, or within, the rabbit aorta wall in vitro and in vivo. Thromb Haemost 71:499, 1994
37. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia colt. Proc Natl Acad Sei USA 85:5879, 1988
38. Braun PJ, Dennis S, Hofsteenge J, Stone SR: Use of sitedirected mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 27:6517, 1988
39. Hatton MWC, Richardson M, Winocour PD: On glucose transport and non-enzymic glycation of proteins in vivo. J Theor Biol 161:481, 1993
40. Phaneuf MD, Ozaki CK, Johnstone MT, Loza J-P, Quist WC, LoGerfo FW: Covalent linkage of streptokinase to recombinant hirudin: A novel thrombolytic agent with antithrombotic properties. Thromb Haemost 71:481, 1994
41. Phaneuf MD, Ito RK, LoGerfo FW: Synthesis and characterization of a recombinant hirudin-albumin complex. Blood Coagul Fibrin 5:641, 1994
42. Eriksson BI, Kalebo P, Ekman S, Lindbratt S, Kerry R, Close P: Direct thrombin inhibition with rec-hirudin (COP 39393) as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 72:227, 1994
43. Antman E, for the TIMI-9A Investigators: Hirudin in myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI-9A) trial. Circulation 90:1638, 1994
44. GUSTO Ha Investigators: Randomised trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631, 1994